Sonidegib

DRUG12 trials

Sponsors

Mayo Clinic, Anne Chang, St. Jude Children's Research Hospital, Melanoma Institute Australia, Sun Pharmaceutical Industries Limited

Conditions

Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic GangliogliomaAnaplastic MeningiomaAnaplastic OligodendrogliomaAtypical Teratoid/Rhabdoid TumorBasal Cell CancerBasal Cell Carcinoma

Phase 1

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

CompletedNCT02129101

Mayo ClinicChronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia +8

Start: 2014-05-31End: 2019-10-25Updated: 2019-10-30

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

CompletedNCT03434262

St. Jude Children's Research HospitalAnaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma +53

Start: 2018-03-05End: 2024-05-24Updated: 2024-05-31

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Active, not recruitingNCT04007744

Mayo ClinicClinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 +19

Start: 2020-02-13End: 2027-07-02Updated: 2026-03-18

Phase 2

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

CompletedNCT02086552

Mayo ClinicRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2014-01-17End: 2021-08-13Updated: 2021-12-03

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

TerminatedNCT02303041

Anne ChangBasal Cell Nevus Syndrome, Carcinoma, Basal Cell, Recurrent Skin Cancer +1

Start: 2015-02-28End: 2017-06-30Updated: 2019-01-29

A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

CompletedNCT03534947

Melanoma Institute AustraliaBasal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Invasive Carcinoma +1

Start: 2019-07-23End: 2025-03-01Updated: 2025-12-16

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

TerminatedNCT04402073

European Organisation for Research and Treatment of Cancer - EORTCMedulloblastoma

Start: 2022-11-11End: 2025-09-10Updated: 2025-10-23

Tailored Sonidegib Schedule After Complete Response in BCC

Active, not recruitingNCT04806646

Gruppo Oncologico del Nord-OvestLocally Advanced Basal Cell Carcinoma

Start: 2021-01-12End: 2026-12-22Target: 21Updated: 2026-06-01

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

RecruitingNCT05669339

University of FloridaHepatocellular Carcinoma

Start: 2024-12-02End: 2027-04-01Target: 12Updated: 2026-07-14

Unknown Phase

Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma

CompletedNCT04066504

Sun Pharmaceutical Industries LimitedBasal Cell Carcinoma

Start: 2019-03-11End: 2025-03-14Updated: 2026-03-18

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

RecruitingNCT05463757

Maastricht University Medical CenterBasal Cell Carcinoma, Basal Cell Nevus Syndrome, Basal Cell Tumor +8

Start: 2021-11-01End: 2026-12-31Target: 80Updated: 2025-04-04

Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma

CompletedNCT07068568

Federico II UniversityBasal Cell Cancer, Basal Cell Carcinoma (BCC), Basal Cell Carcinoma of the Head and Neck +1

Start: 2021-01-11End: 2024-03-20Updated: 2025-07-16

Related Papers

Postauthorization safety study (NISSO) assessing the long-term safety profile of sonidegib in patients with locally advanced basal cell carcinoma: interim analysis from the Spanish cohort.

2025-12-04

CTP-06. Molecular insights into response and resistance in children with relapsed/refractory brain tumors on ribociclib combination therapy: results from SJDAWN

Neuro-Oncology2025-11-01

Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach.

2025-06-01

Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma

BMC Cancer2024-11-146 citations

Abstract B015: CSF liquid biopsies reveal disease status and resistance mechanisms in children undergoing targeted therapy for malignant brain tumors

Clinical Cancer Research2024-11-13

Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies.

2024-06-195 citations

TRLS-16. RESULTS FROM SJDAWN: A ST JUDE CHILDREN’S RESEARCH HOSPITAL PHASE 1 STUDY EVALUATING MOLECULARLY DRIVEN DOUBLET THERAPIES FOR ALL CHILDREN WITH REFRACTORY OR RECURRENT CENTRAL NERVOUS SYSTEM (CNS) MALIGNANT NEOPLASMS AND YOUNG ADULTS WITH SHH MEDULLOBLASTOMA

Neuro-Oncology2024-06-183 citations

BIOM-02. DISSECTING CDK4/6 INHIBITOR RESISTANCE MECHANISMS IN RECURRENT PEDIATRIC BRAIN TUMORS WITH LONGITUDINAL CSF LIQUID BIOPSIES FROM THE SJDAWN CLINICAL TRIAL

Neuro-Oncology2024-06-182 citations

A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-012 citations

Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.

2022-11-24186 citations

Abstract 3031: Characterization of gemcitabine triphosphate formation in mice to aid in the development of a translational tumor model

Cancer Research2020-08-15

Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

Neuro-Oncology Advances2020-01-0117 citations

Factors influencing the intracellular exposure of gemcitabine triphosphate in children with CNS tumors.

Journal of Clinical Oncology2019-05-20